Broadest Coverage Workflow
Multiplexing for Less Complex Samples
TMT LC-MS2 delivers excellent proteome coverage with quantitative results appropriate for biomarker discovery
TMT LC-MS2 is the standard method for analyzing cells and tissues when no phosphopeptide enrichment is required. Typically, the TMT 11-, 18- or 35-plex reagents are used to allow multiplexing across study cohorts. A common study reference is included in all TMT 11-,18- or 35-plex experiments to allow measurement and removal of batch effects and calculation of expression ratios. Using MS2 fragmentation provides the broadest and deepest analysis of the proteome with excellent precision. For more complex samples such as plasma, or where the highest quantitative accuracy is essential we recommend use of TMT LC-MS3.
| Applications | Sample Types | Species | Outcomes |
|---|---|---|---|
| Preclinical Drug Development | Cell culture,Tissue biopsy, Xenograft tumours | Bacteria, Mammal, Insect | Target discovery / validation Mechanism of Action / Resistance |
| Clinical Drug Development | Biopsy tissue, Simple body fluids | Human | Mechanism of Action / Resistance |
| Biomarker Discovery | Biopsy tissue, Simple body fluids | Human, Rodent, Other - inquire | Candidate Biomarker list |
TMT LC-MS2 data is processed through an integrated bioinformatics pipeline providing data integration and pre-processing (DIANA), statistical analysis (FeaST) and functional analysis (FAT) with outputs suitable for further client-led analysis and presentation to management.
The TMT LC-MS2 Workflow Offers:
- Unbiased survey of regulated biological processes in cell lysates and tissue samples with the highest proteome coverage
- Unbiased biomarker discovery in peripheral fluids with the highest coverage
- Combined power of TMT 11-, 18- or 35-plex reagents and Orbitrap mass spectrometers
- Can be combined with a wide range of sample preparation techniques including fractionation and enrichment strategies
- Standardized data outputs in Excel and ‘TSV’ files
- Automated annotation of biological features from UniProtKB, Entrez IDs and Reactome
- Results in 6 to 8 weeks (based on up to a 2 x18-plex sample study)
- Simple report highlighting key biological events and regulated features enriched in the study
- Suitable for enhancing drug discovery, biomarker discovery, pre-clinical and clinical diagnostic assay applications
*Orbitrap™- Trademark of Thermo Fisher